ReviewCritical reviews in oncology/hematology2021
COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications.
Review in Critical reviews in oncology/hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Association Between Serum Ferritin and Disease Severity in COVID-19 Patients in Bangladesh: A Cross-Sectional Study.Cureus · 2026Article
- A novel evaluation indicator for pediatric fulminant myocarditis: diagnostic and prognostic value of the HALP score.BMC pediatrics · 2026Article
- Social disparities in pulmonary embolism and deep vein thrombosis during the coronavirus disease 2019 pandemic from the Nationwide inpatient Sample.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- A model based on PT-INR and age serves as a promising predictor for evaluating mortality risk in patients with SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2025Article
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Innate immune response in acute critical illness: a narrative review.Annals of intensive care · 2024Review
- Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.International journal of molecular sciences · 2024Review
- Vascular Consequences: A Case Report on Posterior Circulation Infarction as a Sequela of COVID-19.Cureus · 2024Article
- Thrombosis and Bleeding Risk Scores Are Strongly Associated with Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study.Journal of clinical medicine · 2024Article
- The Impact of COVID-19 Infection on Abdominal Aortic Aneurysms: Mechanisms and Clinical Implications.Cardiovascular therapeutics · 2024Review
- Review
- What is the Optimal Treatment Regimen of Low-MolecularWeight Heparin in Coronavirus Disease 2019 Pneumonia?Thoracic research and practice · 2023Article
- Lives of Skin Lesions in Monkeypox: Histomorphological, Immunohistochemical, and Clinical Correlations in a Small Case Series.Viruses · 2023Article
- Pulmonary Thrombosis despite Therapeutic Anticoagulation in COVID-19 Pneumonia: A Case Report and Literature Review.Viruses · 2023Review
- Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force.Open forum infectious diseases · 2023Article
- COVID-19, Blood Lipid Changes, and Thrombosis.Biomedicines · 2023Review
- Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.Biomedicines · 2023Review
- Thrombotic Events Develop in 1 Out of 5 Patients Receiving ECMO Support: An 11-Year Referral Centre Experience.Journal of clinical medicine · 2023Article
- Survival implications vs. complications: unraveling the impact of vitamin D adjunctive use in critically ill patients with COVID-19-A multicenter cohort study.Frontiers in medicine · 2023Article
- The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?World journal of emergency surgery : WJES · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coagulopathy of COVID-19 is characterised by significantly elevated D Dimer and fibrinogen, mild thrombocytopenia and a mildly prolonged PT/APTT. A high incidence of thrombotic complications occurs despite standard thromboprophylaxis. The evidence to date supports immunothrombosis as the underlying mechanism for this coagulopathy which is triggered by a hyperinflammatory response and endotheliopathy. A hypercoagulable state results from endothelial damage/activation, complement activation, platelet hyperactivity, release of Extracellular Neutrophil Traps, activation of the coagulation system and a "hypofibrinolytic" state. Significant cross-talk occurs between the innate/adaptive immune system, endothelium and the coagulation system. D dimer has been shown to be the most reliable predictor of disease severity, thrombosis, and overall survival. In this context, targeting pathways upstream of coagulation using novel or repurposed drugs alone or in combination with other anti-thrombotic agents may be a rational approach to prevent the mortality/morbidity due to COVID-19 associated coagulopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.